Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 6Thoracic 1Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Colorectal Neoplasms 10Breast Neoplasms 8Pancreatic Neoplasms 6Neoplasms 5Lung Neoplasms 5Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Carcinoma, Renal Cell 4Melanoma 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Head and Neck Neoplasms 2Spinocerebellar Degenerations 1Solitary Fibrous Tumor, Pleural 1Skin Neoplasms 1Sarcoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Multiple Myeloma 1Mesothelioma, Malignant 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1

Interventions

pembrolizumab 15Nivolumab 9atezolizumab 5Ipilimumab 4Drug Therapy 4Docetaxel 4Radiotherapy 3Radiosurgery 3Paclitaxel 3Gemcitabine 3Cetuximab 3Carboplatin 3Blood Specimen Collection 3temsirolimus 2spartalizumab 2sargramostim 2motexafin gadolinium 2liposomal doxorubicin 2entinostat 2durvalumab 2belinostat 2Sirolimus 2Psychiatric Rehabilitation 2Peripheral Blood Stem Cell Transplantation 2Metformin 2Irinotecan 2Fluorouracil 2Etoposide 2Dexamethasone 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × Capecitabine × Thoracic × Clear all
NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

DEKA Biosciences

Phase 1 Active not recruiting
39 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡